Bio & Health
·
Conformational-State-Selective Membrane Antibodies
Monoclonal Antibodies
Can a designed binder achieve KD below 10 nM and above 100-fold selectivity for a cycling class-B GPCR active state on live cells?
THE QUESTION
Can a designed antibody bind a specified conformational state of a multi-pass membrane target — a class-B GPCR in its active state, or an ion channel in a defined gating state — with KD below 10 nM and above 100-fold selectivity over the other state, where hybridoma and phage routinely fail because the antigen cannot be presented natively?
WORK ORDER
Dwell-time dependence of state-selectivity ratios for designed single-domain binders on cycling GLP-1R
BACKGROUND
What this Apodex Lab is
G-protein-coupled receptors and gated ion channels continuously switch conformations at the surface of living cells. Therapeutic programmes often require antibodies that bind exclusively to the transient, active state of these multi-pass membrane proteins, seeking affinities below 10 nM and over 100-fold selectivity against the resting state. If an antibody associates too slowly while a receptor shifts conformations, apparent selectivity drops, altering target engagement in living tissue.
Published selectivity ratios rely on artificial constructs held rigidly in place by thermostabilising mutations, fusion partners, or detergents. These static preparations prevent the receptor from changing state during measurement, concealing how much selectivity comes from the paratope itself rather than the artificial trapping scaffold. Because hybridoma and phage binders were generated directly against these stabilised objects, paratope affinity and scaffold artefacts were confounded in the same experiment. Whether apparent selectivity survives when a wild-type receptor cycles natively under agonist, and how it scales with the binder association rate constant, has never been measured with sequence-matched controls.
The Monoclonal Antibodies Apodex Lab measures the dwell-time dependence of state selectivity on live mammalian cells expressing wild-type human GLP-1R. Interrogating five sequence-matched designed single-domain binders across pharmacologically set active-state dwell times yields association rate constants, dissociation rate constants, and a median compression factor resolved to ±0.18 log₁₀. If the panel median compression factor falls to 0.4 or below, discovery teams apply a dwell discount to static selectivity ratios and enforce an association-rate floor in target profiles. If the compression factor remains between 0.7 and 1.4, teams retain static screening data and direct engineering effort toward cell-surface epitope accessibility.
WHY NOW
Why the field is spending on an assumption
Drug-discovery programmes open against conformationally gated membrane targets using state-selectivity ratios measured on static, trapped receptor constructs. These preparations prevent the protein from changing state, leaving unmeasured how much selectivity survives when the receptor actively cycles. Researchers can now specify binder sequences directly to generate uniform, sequence-matched recombinant panels. Commercial agonists with distinct residence times on human GLP-1R also allow active-state dwell time to be set pharmacologically on living cells, holding the paratope, cell background, and lipid environment constant without requiring engineered trapped antigens.
WHAT WE’D BUY
What we would ask a laboratory to run
We are not buying the answer. We are buying a measurement with an interval — and the bars it will be compared against.
A test panel of five sequence-matched single-domain antibodies is expressed as recombinant proteins and titrated against living mammalian cells expressing wild-type human GLP-1R. Cells are maintained in three states: short active-state dwell time, long active-state dwell time, and an inactive state. The contract facility measures association and dissociation rate constants to deliver apparent state-selectivity ratios and a dwell compression factor for each binder with 95% confidence intervals. Targeted precision is ±0.25 log₁₀ on kinetic rate constants, ±0.30 log₁₀ on within-condition selectivity ratios, ±0.40 log₁₀ on individual compression factors, and ±0.18 log₁₀ on the five-binder panel median.
SCOPE & LIMITS
The measured kinetic compression applies to monovalent single-domain binders on recombinant cells and does not account for avidity in bivalent antibody formats or native tissue receptor environments.
WHO EXECUTES
The kind of lab that can run this
A membrane-protein biophysics CRO able to express and purify a class-B GPCR (for example GLP-1R or PTH1R) and a gated ion channel in both a conformationally trapped construct and native-lipid nanodisc or whole-cell format, and to run surface plasmon resonance, biolayer interferometry, radioligand and live-cell binding titrations on sequence-matched recombinant antibody panels.
EXECUTOR KIND
wet-lab
WAYS IN
FOR PIs, LABS & CROs
Complete tasks no model can.
Paid per task, credited by name — a “Verified by” line for as long as the discovery it settled exists. You choose the work: browse the tasks above, respond to what you can actually run.
CREATE AN APODEX LAB
Have a question of your own?
Give it its own laboratory. Watch it decompose into an executable manifest.
ASK A FOLLOW-UP QUESTION
Push on our assumptions.
Every Apodex Lab lists what it doesn’t know. Good questions compound.
Every Apodex Lab shares the same verified-knowledge ledger. No laboratory works alone.